Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ningbo NewBay In-Licenses Novel Genentech Oncology Candidate

publication date: Jan 27, 2020

Ningbo NewBay Medical Technology in-licensed greater China rights to a novel small molecule Pan-PIM inhibitor from Genentech, a Roche company. GDC-0570 showed efficacy against multiple myeloma and prostate cancer in preclinical tests, according to the company. The PIM kinases regulate cell metabolism, and GDC-0570 is a potential first-in-class drug candidate. Ningbo NewBay is a subsidiary of Ningbo Tai Kang Medical Technology. NewBay and Tai Kang own greater China rights for two EP4 antagonists from AskAt and global rights for a c-KIT inhibitor from AstraZeneca. More details....

Stock Symbols: (SIX: ROG) (NYSE: AZN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital